Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
465 GBX | 0.00% | +5.44% | +27.40% |
Apr. 24 | EDX Medical to begin trading on Apex segment of AQSE next week | AN |
Apr. 23 | Marula reaches "significant milestone" for Tanzanian graphite projects | AN |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 25.55 times its 2023 earnings per share.
- With an enterprise value anticipated at 4.72 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Financial & Commodity Market Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.40% | 153M | - | ||
+0.50% | 75.94B | B | ||
+11.29% | 21.7B | C+ | ||
+27.19% | 12.54B | C+ | ||
+41.22% | 8.44B | C+ | ||
+1.06% | 7.96B | B- | ||
-1.44% | 2.96B | C+ | ||
+27.08% | 2.55B | C | ||
-7.56% | 1.69B | C | ||
+74.10% | 1.28B | - | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AQX Stock
- Ratings Aquis Exchange PLC